GLP-1 & Incretin Science

What Is Actually Registered, and at What Phase

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Two registered tirzepatide trials cover younger populations. NCT06075667 is a Phase 3 in 160 adolescents aged 12 to 17 with a BMI primary endpoint. NCT05696847 is a completed Phase 1 in 28 children aged 6 to 11 whose primary outcome is adverse events.

Key facts

NCT06075667
Phase 3, n=160, ages 12-17
Its status
Active, not recruiting
Its primary outcome
Percent change from baseline in BMI
Primary completion
2 June 2026
NCT05696847
Phase 1, n=28, ages 6-11
Its status
Completed
Its primary outcome
Treatment-emergent and serious adverse events
Sponsor
Eli Lilly and Company

Why the phase distinction is not pedantry

A Phase 3 in 160 adolescents is designed to establish whether the compound works and is powered for an efficacy endpoint. A Phase 1 in 28 children is designed to characterise safety and tolerability, with adverse events as the primary outcome. Reporting the second as a dedicated paediatric obesity trial with results pending sets an expectation the study was never built to meet.

The age split is deliberate

One trial covers 12 to 17, the other 6 to 11. Those are different populations physiologically, not merely different numbers. Puberty falls between them, and it changes body composition, growth velocity and hormonal context substantially. Regulators generally require separate evidence for separate age bands for this reason.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What the Phase 3 measures

Percent change from baseline in body mass index, per the registry. Not body weight. That follows directly from the participants still growing, and it means the eventual headline number will not be comparable with adult tirzepatide figures however similarly it is reported.

The naming problem, again

NCT06075667 is referred to in coverage under a programme acronym that the registry does not carry; its acronym field is empty. This is the second time on this site that a trial widely discussed by name has turned out to have no registered acronym, the other being the CagriSema head-to-head. Searching a programme name can return nothing while the trial exists.

Where the timeline actually sits

The registry records primary completion for NCT06075667 as 2 June 2026, with the study active and not recruiting. Primary completion means the last participant has reached the primary endpoint assessment, so data exists; publication follows separately and is not automatic or immediate.

The boundary that applies throughout

Tirzepatide is a licensed medicine for adults and is not authorised for paediatric obesity. These are registered trials under clinical supervision with ethics approval. Nothing supplied on this site is tirzepatide, relates to it, or is appropriate for a child in any circumstance.

Quick reference

NCT06075667NCT05696847
Phase31
Enrolment16028
Ages12-176-11
Primary outcome% change in BMIAdverse events
StatusActive, not recruitingCompleted

Frequently asked questions

Is tirzepatide approved for children?

No. It is not authorised for paediatric obesity. Both studies described are registered clinical trials.

Why are there separate trials for different ages?

Puberty falls between the two age bands and changes body composition, growth velocity and hormonal context substantially.

Is the Phase 1 study an efficacy trial?

No. Its primary outcome is treatment-emergent and serious adverse events. It is a safety and tolerability study in 28 children.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.